Dysregulation of heat shock protein 27 expression in oral tongue squamous cell carcinoma by Wang, Anxun et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Dysregulation of heat shock protein 27 expression in oral tongue 
squamous cell carcinoma
Anxun Wang1, Xiqiang Liu2,3, Shihu Sheng1, Hui Ye2,4, Tingsheng Peng5, 
Fei Shi6, David L Crowe2,7 and Xiaofeng Zhou*2,3,7
Address: 1Department of Oral and Maxillofacial Surgery, the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, PR China, 2Center for 
Molecular Biology of Oral Diseases, College of Dentistry, University of Illinois at Chicago, Chicago, USA, 3Research Institute & the Affiliated 
Hospital of Stomatology, Sun Yat-Sen University, Guangzhou, PR China, 4Shanghai Children's Medical Center, Shanghai Jiao-Tong University, 
Shanghai, PR China, 5Department of Pathology, the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, PR China, 6Division of 
Epidemiology and Biostatistics, School of Public Health, University of Illinois at Chicago, Chicago, USA and 7Graduate College, UIC Cancer 
Center, University of Illinois at Chicago, Chicago, USA
Email: Anxun Wang - anxunwang@yahoo.com; Xiqiang Liu - liuxiqia@uic.edu; Shihu Sheng - shengshihu@yahoo.com.cn; 
Hui Ye - huiye@uic.edu; Tingsheng Peng - tshpeng@yahoo.com; Fei Shi - feishi2@uic.edu; David L Crowe - dlcrowe@uic.edu; 
Xiaofeng Zhou* - xfzhou@uic.edu
* Corresponding author    
Abstract
Background: Recent proteomic studies identified Hsp27 as a highly over-expressed protein in
oral squamous cell carcinoma (OSCC). Clinical studies that attempted to evaluate the prognostic
values of Hsp27 yielded inconsistent results, which may be due to inclusion of OSCC cases from
multiple anatomic sites. In this study, to determine the utility of Hsp27 for prognosis, we focused
on oral tongue SCC (OTSCC), one of the most aggressive forms of OSCC.
Methods: Archival clinical samples of 15 normal oral tongue mucosa, 31 dysplastic lesions, 80
primary OTSCC, and 32 lymph node metastases were examined for Hsp27 expression by
immunohistochemistry (IHC). Statistical analyses were carried out to assess the prognostic value
of Hsp27 expression for patients with this disease.
Results: Dysregulation of Hsp27 expression was observed in dysplastic lesions, primary OTSCC,
and lymph node metastases, and appears to be associated with disease progression. Statistical
analysis revealed that the reduced Hsp27 expression in primary tumor tissue was associated with
poor differentiation. Furthermore, the higher expression of Hsp27 was correlated with better
overall survival.
Conclusion: Our study confirmed that the dysregulation of Hsp27 expression is a frequent event
during the progression of OTSCC. The expression of Hsp27 appears to be an independent
prognostic marker for patients with this disease.
Background
Oral squamous cell carcinoma (OSCC) is a complex dis-
ease arising in various sites, such as the oral cavity and
oropharynx including the oral tongue and the base of the
tongue. Tumors from these different sites have distinct
clinical presentations and outcomes, and are associated
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with different risk factors [1] and genetic characteristics
[2]. In this study, we focused on oral tongue (also known
as mobile tongue), one of the most common sites for
OSCCs. The oral tongue SCC (OTSCC) is more aggressive
than other forms of OSCCs, with a propensity for rapid
local invasion and spread [3]. The incidence of OTSCC is
actually increasing in young and middle age groups [4-6].
Mammalian Hsp27 belongs to the family of proteins that
display an enhanced expression in response to various
stresses (e.g., heat shock). Several members of the Hsps
family (e.g., Hsp90, Hsp70, Hsp27) have been implicated
in tumorigenesis, which may be related to their ability to
protect cells against spontaneous or stimulated pro-
grammed cell death [7]. The cytoprotective properties of
the Hsps are closely linked to their primary functions as
molecular chaperones. A critical function of Hsp27 is the
ability to increase the resistance of cells to oxidative inju-
ries. Hsp27 expression correlates with decreased levels of
reactive oxygen species (ROS) and nitric oxide (NO.) [8-
11].
The enhanced expression of Hsp27 has been associated
with poor prognosis in several tumor types (e.g., gastric
[12,13], liver [14] and prostate carcinoma [15]), but good
prognosis in others (endometrial adenocarcinomas
[16,17] and oesophageal cancer [18,19]). Several pro-
teomic studies identified Hsp27 as a highly over-
expressed protein in OSCC [20,21]. Our recent proteomic
study also demonstrated that higher Hsp27 expression is
associated with tongue SCC invasion and metastasis [22].
Several clinical studies have attempted to evaluate the
prognostic value of Hsp27 for OSCC, yet yielded incon-
sistent results [23-28]. This apparent contradiction may
partly be due to the inclusion of OSCC cases from multi-
ple anatomic sites. In this study, we evaluate the prognos-
tic significance of Hsp27 focusing on OTSCC, one of the
most aggressive forms of OSCC.
Methods
Patients and tissues
The archived tissue samples from 80 cases of OTSCC, 31
cases of dysplastic lesions of the oral tongue and 15 nor-
mal tongue biopsies were utilized in this study. Clinical
characterization of the OTSSC patients is summarized in
Table 1. All OTSCC patients had received curative surgery
(resection of the primary tumor and radical neck dissec-
tion). None of the patients had received any form of adju-
vant therapy prior to their surgery. The tumor extent was
classified according to the TMN system by UICC, and the
tumor grade was classified according to the WHO classifi-
cation of histological differentiation. Survival was calcu-
Table 1: Clinical Characterization of the oral tongue squamous cell carcinoma (OTSCC) Patients*
All OTSCCs
(n = 80)
OTSCCs with follow-up data
(n = 42)
Dysplastic lesions
(n = 31)
Normal
(n = 15)
Age Median (Range) 48 (21–77) 46.5 (21–73) 51 (30–82) 47 (30–72)
Gender  Male: n (%) 43 (53.75) 20 (47.62) 17 (54.84) 6 (40.00)
Female: n (%) 37 (46.25) 22 (52.38) 14 (45.16) 9 (60.00)
Anatomic Site Tongue: n (%) 80 (100) 42 (100) 31 (100) 15 (100)
Pathological T Stage Stage 4: n (%) 5 (6.25) 4 (9.52)
Stage 3: n (%) 14 (17.50) 8 (19.05)
Stage 2: n (%) 38 (47.50) 21 (50.00)
Stage 1: n (%) 23 (28.75) 9 (21.43)
Pathological N Stage Stage 2: n (%) 13 (16.25) 8 (19.05)
Stage 1: n (%) 19 (23.75) 12 (28.57)
Stage 0: n (%) 48 (60.00) 22 (52.38)
Clinical Stage Stage 4: n (%) 15 (18.75) 10 (23.81)
Stage 3: n (%) 25 (31.25) 16 (38.09)
Stage 2: n (%) 18 (22.50) 7 (16.67)
Stage 1: n (%) 22 (27.50) 9 (21.43)
Grade (Differentiation) Well: n (%) 46 (57.50) 25 (59.52)
Mod: n (%) 20 (25.00) 7 (16.67)
Poor: n (%) 14 (17.50) 10 (23.81)
* The M stage data is not available.BMC Cancer 2009, 9:167 http://www.biomedcentral.com/1471-2407/9/167
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lated based on the date of surgery and the date of latest
follow-up (or death). This study was approved by the eth-
ical committee of The First Affiliated Hospital, Sun Yat-
Sen University and the Institutional Review Boards (IRB)
at University of Illinois at Chicago, IL.
Immunohistochemistry analysis
Tissue samples were dehydrated in an ethanol series,
cleared in xylene, and embedded in paraffin. Five-
micrometer sections were prepared and mounted on poly-
L-lysine-coated slides. Representative sections were
stained with H&E and histologically evaluated by a
pathologist. Immunohistochemical analysis was done
using a commercially available kit (Invitrogen, Carlsbad,
CA). Sections were incubated at 60°C for 30 min and
deparaffinized in xylene. Endogenous peroxidase activity
was quenched by incubation in a 9:1 methanol/30%
hydrogen peroxide solution for 10 min at room tempera-
ture. Sections were rehydrated in PBS (pH 7.4) for 10 min
at room temperature. Sections were then blocked with
10% normal serum for 10 min at room temperature fol-
lowed by incubation with anti-Hsp27 and anti-Ki67 anti-
bodies (ABCam) at a dilution of 1:200 for 16 h at room
temperature. After washing thrice in PBS, the sections
were incubated with secondary antibody conjugated to
biotin for 10 min at room temperature. After additional
washing in PBS, the sections were incubated with strepta-
vidin-conjugated horseradish peroxidase enzyme for 10
min at room temperature. Following final washes in PBS,
antigen-antibody complexes were detected by incubation
with a hydrogen peroxide substrate solution containing
aminoethylcarbazole chromogen reagent. Slides were
rinsed in distilled water, coverslipped using aqueous
mounting medium, and allowed to dry at room tempera-
ture. The relative intensities of the completed immunohis-
tochemical reactions were evaluated using light
microscopy by 3 independent trained observers who were
unaware of the clinical data. All areas of tumor cells
within each section were analyzed. All tumor cells in ten
random high power fields were counted. A scale of 0 to 3
was used to score relative intensity, with 0 corresponding
to no detectable immunoreactivity and 1, 2, and 3 equiv-
alent to low, moderate, and high staining, respectively. As
for Ki67, nuclear staining was evaluated and the Ki67
index was calculated as the percentage of positive stained
nuclei of all the tumor cells in ten randomly selected high
power fields.
Statistical analysis
Spearman Correlation Coefficient was used to assess cor-
relations among the gene expression and clinical and his-
topathological parameters. One-way ANOVA was used to
assess the association of gene expression (e.g., Hsp27 and
Ki67) with histopathological parameters (e.g., grading).
Kaplan-Meier plots were constructed to present the sur-
vival outcomes of high Hsp27 cases (moderate to high
staining) and low Hsp27 cases (no or low staining). Cox
regression was used for both univariate and multivariate
analysis. For multivariate analysis, age, gender, patholog-
ical T-stage (pT), pathological N-stage (pN), and clinical
stages, grade, Ki67 index, and Hsp27 expression were con-
sidered as co-variates. For all statistical analyses, p < 0.05
was considered statistically significant.
Results
As illustrated in Figure 1, predominantly cytoplasmic
staining for Hsp27 was observed in suprabasal keratinoc-
ytes in normal mucosa (Figure 1A). In general, the basal
keratinocytes were not immunolabelled by anti-Hsp27
antibody. Among 15 normal mucosa that we examined, 4
cases (26.67%) showed no Hsp27 staining, 8 cases
(53.33%) showed low staining, 2 cases (13.33%) showed
moderate staining, and 1 case (6.67%) showed high stain-
ing. In dysplastic lesions (Figure 1B), the Hsp27 staining
was observed in both suprabasal and basal keratinocytes.
Of the 31 dysplastic lesions, 1 case (3.23%) showed no
Hsp27 staining, 5 cases (16.13%) showed low staining,
11 cases (35.48%) showed moderate staining, and 14
cases (45.16%) showed high staining. In SCC (Figure 1C,
D, E), diffuse Hsp27 staining was observed, where the
high Hsp27 expression appears to be associated with dif-
ferentiated areas. Of the 80 cases of primary OTSCC cases,
1 case (1.25%) showed no Hsp27 staining, 20 cases
(25%) showed low staining, 42 cases (52.5%) showed
moderate staining, and 17 cases (21.25%) showed high
staining. For the 32 cases of lymph node metastatic dis-
ease (Figure 1F), low staining was observed in 8 cases
(25%), moderate staining was observed in 12 cases
(37.5%), and high staining was observed in 12 cases
(37.5%). Thus, the dysregulation of Hsp27 consists of
both the changes in cell population expressing this gene
and the alterations in expression level. This change in
Hsp27 expression pattern is consistent with our previous
observations [22].
Correlations were tested among gene expression (e.g.,
Hsp27 and Ki67), clinical and Hsp27 expression (Table
2). As expected, strong correlations were observed among
pT, pN, and Clinical stage. While correlation between
Ki67 index and grading was observed (p < 0.05), a signif-
icant inverse correlation was observed between Hsp27
expression and grading (p < 0.01). Interestingly, correla-
tion between Hsp27 expression and age was also observed
(p < 0.05).
As illustrated in Figure 1C, D, and 1E, the higher expres-
sion of Hsp27 was observed in well and moderately differ-
entiated OTSCC, and lower Hsp27 expression was
observed in poorly differentiated cases. Statistical analysis
revealed that the Hsp27 expression level in primaryBMC Cancer 2009, 9:167 http://www.biomedcentral.com/1471-2407/9/167
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OTSCC is associated with differentiation (p = 0.0259)
(Table 3). A marginal association was also observed
between Ki67 index and differentiation (p = 0.0613).
Among 80 cases of OTSCC that we examined, follow-up
results were available on 42 cases (52.5%). Median dura-
tion of follow-up was 31 months (range 8–99). Among
these 42 cases, 12 cases (28.57%) showed low Hsp27
staining, 18 cases (42.86%) showed moderate Hsp27
staining, and 12 cases (28.57%) showed high Hsp27
staining. As illustrated in Figure 2, a striking difference in
median survival time was observed between high (immu-
nohistochemical score of 2 or 3) Hsp27 expression group
(over 60 months) and low (immunohistochemical score
of 0 or 1) Hsp27 expression groups (less than 30 months).
Both univariate and multivariate analysis demonstrated
the positive effect of high Hsp27 expression for prognosis
(Table 4). Based on univariate analysis, the effects of pT
and clinical stages on prognosis were also observed.
Immunohistochemistry analyses of Hsp27 expression on normal tongue, dysplastic lesions, primary oral tongue squamous cell  carcinoma (OTSCC) and lymph node metastasis tissue samples Figure 1
Immunohistochemistry analyses of Hsp27 expression on normal tongue, dysplastic lesions, primary oral 
tongue squamous cell carcinoma (OTSCC) and lymph node metastasis tissue samples. Immunohistochemistry 
analyses for Hsp27 were performed as described in Material and Methods on A: normal tongue mucosa (n = 15), B: dysplastic 
lesions (n = 31), C: well differentiated primary OTSCC (n = 46), D: moderately differentiated primary OTSCC (n = 20), E: 
poorly differentiated primary OTSCC (n = 14), and F: lymph node metastasis (n = 32). Representative Images (×200) were 
shown.
Table 2: Correlations among clinical and histopathological features of primary OTSCC*
Age Gender pT stage pN stage C stage Grade Ki67 Hsp27
Age 0.01 -0.04 -0.13 -0.06 -0.10 0.18 0.26 **
Gender 0.12 0.04 0.12 0.00 0.07 -0.03
pT stage 0.44 *** 0.81 *** -0.14 -0.14 0.00
pN stage 0.78 *** 0.06 -0.03 0.16
C stage -0.01 -0.07 0.06
Grade 0.23 ** -0.29 ***
Ki67 0.04
Hsp27
*Spearman Correlation Coefficients were presented. pT: pathological T-stage; pN: pathological N-stage.
** p < 0.05
*** p < 0.01BMC Cancer 2009, 9:167 http://www.biomedcentral.com/1471-2407/9/167
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Discussion and conclusion
Heat shock proteins (HSPs) have been implicated in mul-
tiple aspects of tumorigenesis [29]. Hsp27 belongs to a
sub-family of small heat shock proteins that are character-
ized by low molecular masses (12–43 kDa). High levels of
Hsp27 expression have been observed in many types of
cancers, and tumorigenic potential of Hsp27 expression
has been observed in experimental models [30,31]. Its
antiapoptotic effect has been well established [32]. The
dysregulation of Hsp27 has also been suggested to con-
tribute to invasion and metastasis [33]. More importantly,
Hsp27 expression is associated with resistance to cyto-
static anticancer drugs (e.g., cisplatin, vincristine and col-
chicine) and radiation therapy [34-37]. It is striking that
Hsp27 is associated with poor prognosis in several tumor
types (gastric [12,13], liver [14] and prostate carcinoma
[15]), but good prognosis in others (endometrial adeno-
carcinomas [16,17] and oesophageal cancer [18,19]).
These apparent differences in the prognosis of Hsp27 may
be partly due to the difference in biological natures of
these cancer types, as well as the different treatment
options (some of them may be influenced by Hsp27) for
these cancers. Collectively, these facts signify the pro-
found roles of Hsp27 in many aspects of tumor progres-
sion and response to therapy.
Table 3: Association of Hsp27 expression and Ki67 index with differentiation*
Hsp27 (IHC) Ki67 index
n Average Variance Average Variance
Well 46 1.90 0.45 0.225 0.019
Moderately 20 1.74 0.47 0.302 0.025
Poorly 14 1.34 0.39 0.316 0.040
(p = 0.025872) (p = 0.061275)
*One-way ANOVA was used to assess the association of Hsp27 and Ki67 with grading.
The effects of Hsp27 expression on prognosis Figure 2
The effects of Hsp27 expression on prognosis. Kaplan-Meier plots of overall survival in patient groups defined by Hsp27 
immunohistochemistry (High Hsp27: moderate to high staining, Low Hsp27: no detectable or low staining). The difference in 
survival rates is statistically significant (p < 0.05).
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Currently, the prognostic significance of Hsp27 for OSCC
is not clear. While correlation of Hsp27 expression with
survival rate was observed in some studies [24,25,28],
inverse correlation with survival was implicated in a dif-
ferent study [27], and no prognostic significance was
observed by other studies [23,26]. These inconsistencies
may in part be due to the heterogeneity in oncogenic
pathways. Distinct oncogenic pathways may give rise to a
common malignant phenotype (i.e. there may be several
different "ways" to get oral cancers). If there are multiple
distinct etiologic possibilities (e.g., tobacco smoking,
alcohol abuse, HPV infection), and not all are necessary to
produce the malignant phenotype, then some of the
oncogenic pathways may remain "normal" despite the
fact that cancer develops. This may be especially true for
OSCC, which arises in various sites (e.g., oral cavity and
oropharynx). Tumors from these different sites have dis-
tinct clinical presentations and clinical outcomes, and are
associated with different risk factors [1] and genetic char-
acteristics [2]. This again complicates the evaluation of
prognostic markers because no single etiologic event is
consistently present in all cases.
In our present study, by focusing on just one anatomic site
(oral tongue), we were able to partially minimize the
genetic variation and microenvironment effects among
intraoral sites. Our results clearly demonstrated that
higher expression level of Hsp27 in primary OTSCC is
directly correlated with overall survival rate. Our results
also confirmed that the dysregulation of Hsp27 expres-
sion is a progressive event that accompanies the OTSCC
progression. While the Hsp27 expression is restricted to
differentiated suprabasal keratinocytes in normal mucosa,
the Hsp27 is expressed in both suprabasal and basal kerat-
inocytes of dysplastic lesions, and then exhibits a diffuse
expression pattern in primary OTSCC and metastatic dis-
ease. In addition, the reduced Hsp27 expression in pri-
mary tumor tissue is associated with poor differentiation.
Interestingly, correlation between Hsp27 expression and
age was also observed (p < 0.05). A similar observation
regarding age and Hsp27 expression in OSCC was also
reported in a previous study [24]. Currently, the clinical
relevance of this observation is not clear.
It should be noticed that the biological activities of Hsp27
are regulated by phosphorylation of its serines by
mitogen-activated protein kinases associated protein
kinases (MAPKAPKs) which are themselves activated by
phosphorylation by MAP p38 protein kinase [38,39]. In
our present study, we do not know the phosphorylation
status of the Hsp27. Additional studies may be warranted
to further evaluate the prognostic value of Hsp27 which
incorporates additional stratification of the phosphoryla-
tion status.
In summary, we demonstrated that the dysregulation of
Hsp27 expression is a frequent event during the progres-
sion of OTSCC. The expression level of Hsp27 is associ-
ated with differentiation grade, and reduced expression of
Hsp27 is correlated with poor overall survival. Our data
suggested that Hsp27 expression may provide prognostic
value for patients with OTSCC.
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